Is BPC-157 Safe for Women? What the Evidence Says About Fertility and Side Effects

What does the evidence say about BPC-157 safety for women?

Quick answer

BPC-157 has not been shown to be safe for women. A two-person IV pilot, including one 68-year-old woman, reported no side effects, but that cannot establish safety for fertility, hormones, pregnancy, breastfeeding, or long-term use.

Reviewed by Taylor Anderson, RN · Aesthetic Registered Nurse · Updated September 1, 2026

Key takeaways

Only one woman appears in the direct human safety study reviewed here: a 68-year-old participant in a two-person IV pilot.
Small human studies reported no adverse effects, but they were not large or long enough to identify uncommon, reproductive, or chronic risks.
Human studies have not reliably tested fertility, ovarian reserve, menstrual cycles, pregnancy, breastfeeding, or female-specific dosing.
The evidence does not establish wrinkle reduction, younger-looking skin, or other anti-aging benefits.
Before considering BPC-157, define the goal, review reproductive plans, ask about monitoring, and compare options with stronger human evidence.

If you are considering BPC-157 for recovery, pain, or appearance, the honest answer is that its safety for women has not been established. Human research is very small, female-specific reproductive safety has not been properly studied, and a two-person IV pilot, including one woman, reported no side effects but cannot establish long-term safety.

Women often look to BPC-157 for faster recovery, less pain, or a younger appearance that matches how they feel. The available research does not prove those results or answer the safety questions that matter for fertility, hormones, pregnancy, breastfeeding, or years of use. Here is what the published evidence measured, what it missed, and what to ask before you spend time or money.

What the Evidence Says About BPC-157 Safety for Women

Current evidence cannot establish that BPC-157 is safe for women. Small human pilots reported no adverse effects, but their size and design cannot reveal uncommon, reproductive, or long-term risks.

Question	Evidence-based answer
Has BPC-157 been shown to be safe for women?	No. Female-specific safety has not been established.
What is the strongest human signal?	A two-person IV pilot included one 68-year-old woman and reported no side effects.
What cannot be concluded?	That BPC-157 is safe during pregnancy, breastfeeding, family planning, long-term use, or routine female dosing.

The Florida IV pilot enrolled a 68-year-old woman and a 58-year-old man. Infusions of up to 20 mg produced no reported side effects or measurable changes in selected heart, liver, kidney, thyroid, or blood-glucose biomarkers, according to the PubMed report.

That single female datapoint is the only direct human safety observation tied to a woman in the sources reviewed here. One participant cannot show how BPC-157 behaves across different ages, hormonal states, or years of use.

For a broader overview of the question, see Is BPC-157 Safe for Women?.

What Human Studies Have Actually Tested

Human data on BPC-157 remain limited to a handful of small pilots. A 2025 narrative review states that only three pilot studies had examined BPC-157 in humans, including work involving knee pain, interstitial cystitis, and IV safety or pharmacokinetics. The review also notes that rigorous, large-scale trials are lacking. Read the narrative review in PubMed or full text in PMC.

Evidence	Finding	Main limitation
Intravenous pilot	Two healthy adults had no reported adverse effects.	Two participants cannot detect uncommon or long-term risks.
Other human pilot studies	Reviews identify studies involving knee pain, interstitial cystitis, and IV safety or pharmacokinetics.	These were not large, controlled trials designed around women’s health.
Fertility and reproductive outcomes	No large trials assess conception, live birth, or ovarian reserve.	Safety and effectiveness for these outcomes remain uncertain.

The studies did not provide a reliable answer for women’s health outcomes. That means a clinician cannot point to strong human evidence when a woman asks whether BPC-157 is safe for her specific reproductive or hormonal situation.

The Female-Specific Questions That Remain Unanswered

A January 2026 review from Inovi Fertility describes human fertility data as virtually nonexistent. It says reproductive toxicity, teratogenicity, and long-term endocrine effects have not been robustly studied. The review also identifies missing information about absorption, distribution, metabolism, excretion, and exposure in reproductive organs. Read the Inovi Fertility review.

Question	What the evidence shows
Could it affect estrogen, progesterone, or menstrual cycles?	No reliable human studies establish these effects.
Could it affect fertility or ovarian function?	No large trials assess conception, live birth, ovarian reserve, or reproductive toxicity.
Is it safe during pregnancy or breastfeeding?	These uses and potential risks remain unstudied.
Is there a female-specific dose?	Dose-response, pharmacokinetics, and reproductive-organ exposure have not been adequately characterized.

A 2025 analysis from Swolverine reaches a similar conclusion. It reports no studies confirming how BPC-157 interacts with estrogen, progesterone, or menstrual cycles, and says risks around fertility, pregnancy, and breastfeeding remain unstudied. Those claims are based largely on the absence of controlled female trials, not proof that harm will occur.

If you track your cycle, plan to conceive, or manage perimenopausal symptoms, the current literature does not give you a clear safety answer.

Possible Risks Versus Reported Side Effects

Small human pilots reported no adverse effects. A preclinical safety evaluation found no teratogenic, genotoxic, anaphylactic, or local toxic effects at high doses in animals. Animal findings do not establish safety in women.

The 2025 musculoskeletal review discusses possible concerns based on laboratory and animal findings, including pathologic angiogenesis, toxic metabolites, and excessive nitric oxide production. These are proposed risks, not confirmed human side effects. They need direct clinical testing before anyone can quantify what they mean for women.

A sports-medicine systematic review found that human safety had not been assessed in the studies it included and that animal follow-up beyond six weeks was absent. Its scope differs from the later two-person IV pilot, but both sources point to the same practical problem: the evidence is too limited to answer chronic-use questions.

No reported adverse events in a tiny study is different from demonstrated safety. That distinction matters when the outcome involves your fertility window or long-term appearance goals.

What This Means for Anti-Aging and Appearance Goals

The human studies cited in published reviews did not measure wrinkle reduction, skin aging, or appearance outcomes. Claims that BPC-157 will make women look younger therefore sit outside the available human data.

Claim	What has been studied	What remains unproven
Younger-looking skin or fewer wrinkles	The cited human studies did not establish wrinkle, skin-aging, or appearance outcomes.	A reliable anti-aging benefit in women.
Regeneration or faster healing	Animal and cell models suggest tissue-repair and vascular effects.	That these findings translate into meaningful cosmetic or wellness benefits.
An expensive treatment must work better	Study quality and measured outcomes, not cost, determine evidentiary strength.	That paying more improves results or safety.

A 2025 literature and patent review notes promising preclinical activity but emphasizes the lack of comprehensive human studies confirming clinical benefits. You can read the review on PubMed. Animal data on angiogenesis and collagen formation do not automatically produce visible results in women.

If appearance is your goal, compare BPC-157 with treatments that have actually measured skin or hair outcomes. The skin hub and hair hub cover options with more specific human data for those concerns.

Questions to Ask Before Considering BPC-157

Before you invest in any provider or product, ask:

Question to ask	Why it matters
What result am I trying to get?	Recovery, pain relief, appearance, and other goals require different evidence.
What is known about my reproductive plans?	Fertility, pregnancy, breastfeeding, menstrual cycles, and hormonal conditions have not been adequately studied.
What are the proposed route, duration, monitoring plan, and stopping criteria?	The available studies do not establish a standard female regimen.
Is there an option with stronger human evidence for the same goal?	A more studied option may give you a clearer benefit and safety discussion.

Get Hot or Die currently prescribes and dispenses medication. If you want to compare care options with your goals and budget in mind, start with the Get Hot or Die personalized quiz.

For questions about provider choices, see Best Peptide Telehealth Providers for Women. For cost context, read BPC-157 Cost Per Month: What You Will Actually Pay, keeping in mind that the evidence does not show that a higher price means better results or safety.

Sources and Notes

This article was checked on September 1, 2026. The evidence remains limited, and several reviews do not provide enough follow-up to answer long-term or reproductive safety questions.

FAQ

Is BPC-157 proven safe for women?

No. Female-specific safety has not been established. The only direct female participant identified here was a 68-year-old woman in a two-person IV pilot.

Have human studies found side effects from BPC-157?

The small human pilots summarized here reported no adverse effects, but their size and follow-up cannot rule out uncommon or long-term risks.

Could BPC-157 affect fertility, periods, pregnancy, or breastfeeding?

It is unknown. Human studies have not robustly evaluated menstrual cycles, hormones, conception, live birth, reproductive toxicity, pregnancy, or breastfeeding.

Does BPC-157 have proven anti-aging or appearance benefits?

No. The available human research has not established wrinkle reduction, skin-aging benefits, or other appearance outcomes.

What should women ask before considering BPC-157?

Ask what human evidence supports your goal, review fertility and pregnancy plans, clarify the proposed route and duration, discuss monitoring, and compare better-studied options.

Ready to make a move?

Answer three questions to see the options, prices, and providers that fit your goals.

See My Plan

Questions women actually ask